162 related articles for article (PubMed ID: 35877084)
1. Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
James ND; Ingleby FC; Clarke NW; Amos CL; Attard G; Brawley CD; Chowdhury S; Cross W; Dearnaley DP; Gilbert DC; Gillessen S; Jones RJ; Langley RE; Macnair A; Malik ZI; Mason MD; Matheson DJ; Millman R; Parker CC; Rush HL; Russell JM; Au C; Ritchie AWS; Mestre RP; Ahmed I; Birtle AJ; Brock SJ; Das P; Ford VA; Gray EK; Hughes RJ; Manetta CB; McLaren DB; Nikapota AD; O'Sullivan JM; Perna C; Peedell C; Protheroe AS; Sundar S; Tanguay JS; Tolan SP; Wagstaff J; Wallace JB; Wylie JP; Zarkar A; Parmar MKB; Sydes MR
JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35877084
[TBL] [Abstract][Full Text] [Related]
2. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Clarke NW; Ali A; Ingleby FC; Hoyle A; Amos CL; Attard G; Brawley CD; Calvert J; Chowdhury S; Cook A; Cross W; Dearnaley DP; Douis H; Gilbert D; Gillessen S; Jones RJ; Langley RE; MacNair A; Malik Z; Mason MD; Matheson D; Millman R; Parker CC; Ritchie AWS; Rush H; Russell JM; Brown J; Beesley S; Birtle A; Capaldi L; Gale J; Gibbs S; Lydon A; Nikapota A; Omlin A; O'Sullivan JM; Parikh O; Protheroe A; Rudman S; Srihari NN; Simms M; Tanguay JS; Tolan S; Wagstaff J; Wallace J; Wylie J; Zarkar A; Sydes MR; Parmar MKB; James ND
Ann Oncol; 2019 Dec; 30(12):1992-2003. PubMed ID: 31560068
[TBL] [Abstract][Full Text] [Related]
3. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Sydes MR; Spears MR; Mason MD; Clarke NW; Dearnaley DP; de Bono JS; Attard G; Chowdhury S; Cross W; Gillessen S; Malik ZI; Jones R; Parker CC; Ritchie AWS; Russell JM; Millman R; Matheson D; Amos C; Gilson C; Birtle A; Brock S; Capaldi L; Chakraborti P; Choudhury A; Evans L; Ford D; Gale J; Gibbs S; Gilbert DC; Hughes R; McLaren D; Lester JF; Nikapota A; O'Sullivan J; Parikh O; Peedell C; Protheroe A; Rudman SM; Shaffer R; Sheehan D; Simms M; Srihari N; Strebel R; Sundar S; Tolan S; Tsang D; Varughese M; Wagstaff J; Parmar MKB; James ND;
Ann Oncol; 2018 May; 29(5):1235-1248. PubMed ID: 29529169
[TBL] [Abstract][Full Text] [Related]
4. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Spears MR; Ritchie AW; Parker CC; Russell JM; Attard G; de Bono J; Cross W; Jones RJ; Thalmann G; Amos C; Matheson D; Millman R; Alzouebi M; Beesley S; Birtle AJ; Brock S; Cathomas R; Chakraborti P; Chowdhury S; Cook A; Elliott T; Gale J; Gibbs S; Graham JD; Hetherington J; Hughes R; Laing R; McKinna F; McLaren DB; O'Sullivan JM; Parikh O; Peedell C; Protheroe A; Robinson AJ; Srihari N; Srinivasan R; Staffurth J; Sundar S; Tolan S; Tsang D; Wagstaff J; Parmar MK;
Lancet; 2016 Mar; 387(10024):1163-77. PubMed ID: 26719232
[TBL] [Abstract][Full Text] [Related]
5. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R
JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract][Full Text] [Related]
8. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
Sartor O; Karrison TG; Sandler HM; Gomella LG; Amin MB; Purdy J; Michalski JM; Garzotto MG; Pervez N; Balogh AG; Rodrigues GB; Souhami L; Reaume MN; Williams SG; Hannan R; Jones CU; Horwitz EM; Rodgers JP; Feng FY; Rosenthal SA
Eur Urol; 2023 Aug; 84(2):156-163. PubMed ID: 37179241
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).
Morris MJ; Mota JM; Lacuna K; Hilden P; Gleave M; Carducci MA; Saad F; Cohn ED; Filipenko J; Heller G; Shore N; Armstrong AJ; Scher HI
Eur Urol Oncol; 2021 Aug; 4(4):543-552. PubMed ID: 34020931
[TBL] [Abstract][Full Text] [Related]
10. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Parker CC; James ND; Brawley CD; Clarke NW; Ali A; Amos CL; Attard G; Chowdhury S; Cook A; Cross W; Dearnaley DP; Douis H; Gilbert DC; Gilson C; Gillessen S; Hoyle A; Jones RJ; Langley RE; Malik ZI; Mason MD; Matheson D; Millman R; Rauchenberger M; Rush H; Russell JM; Sweeney H; Bahl A; Birtle A; Capaldi L; Din O; Ford D; Gale J; Henry A; Hoskin P; Kagzi M; Lydon A; O'Sullivan JM; Paisey SA; Parikh O; Pudney D; Ramani V; Robson P; Srihari NN; Tanguay J; Parmar MKB; Sydes MR;
PLoS Med; 2022 Jun; 19(6):e1003998. PubMed ID: 35671327
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
James ND; Sydes MR; Mason MD; Clarke NW; Anderson J; Dearnaley DP; Dwyer J; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann GN; Bertelli G; Birtle AJ; O'Sullivan JM; Protheroe A; Sheehan D; Srihari N; Parmar MK;
Lancet Oncol; 2012 May; 13(5):549-58. PubMed ID: 22452894
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
Carles J; Gallardo E; Doménech M; Font A; Bellmunt J; Figols M; Mellado B; Sáez MI; Suárez C; Méndez MJ; Maroto P; Luque R; de Portugal T; Aldabo R; Bonfill T; Morales-Barrera R; García J; Maciá S; Maldonado X; Foro P
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):344-352. PubMed ID: 30321689
[TBL] [Abstract][Full Text] [Related]
14. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
15. Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis.
Mahal BA; Kwak L; Xie W; Eastham JA; James ND; Sandler HM; Feng FY; Brihoum M; Fizazi K; Sweeney C; Ravi P; D'Amico AV
JAMA Netw Open; 2023 Nov; 6(11):e2340787. PubMed ID: 37910103
[TBL] [Abstract][Full Text] [Related]
16. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
[TBL] [Abstract][Full Text] [Related]
17. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ali A; Hoyle A; Haran ÁM; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Dearnaley D; Attard G; Gillessen S; Parmar MKB; Parker CC; Sydes MR; James ND; Clarke NW
JAMA Oncol; 2021 Apr; 7(4):555-563. PubMed ID: 33599706
[TBL] [Abstract][Full Text] [Related]
18. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Woods BS; Sideris E; Sydes MR; Gannon MR; Parmar MKB; Alzouebi M; Attard G; Birtle AJ; Brock S; Cathomas R; Chakraborti PR; Cook A; Cross WR; Dearnaley DP; Gale J; Gibbs S; Graham JD; Hughes R; Jones RJ; Laing R; Mason MD; Matheson D; McLaren DB; Millman R; O'Sullivan JM; Parikh O; Parker CC; Peedell C; Protheroe A; Ritchie AWS; Robinson A; Russell JM; Simms MS; Srihari NN; Srinivasan R; Staffurth JN; Sundar S; Thalmann GN; Tolan S; Tran ATH; Tsang D; Wagstaff J; James ND; Sculpher MJ
Eur Urol Oncol; 2018 Dec; 1(6):449-458. PubMed ID: 31158087
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
James ND; Clarke NW; Cook A; Ali A; Hoyle AP; Attard G; Brawley CD; Chowdhury S; Cross WR; Dearnaley DP; de Bono JS; Diaz-Montana C; Gilbert D; Gillessen S; Gilson C; Jones RJ; Langley RE; Malik ZI; Matheson DJ; Millman R; Parker CC; Pugh C; Rush H; Russell JM; Berthold DR; Buckner ML; Mason MD; Ritchie AWS; Birtle AJ; Brock SJ; Das P; Ford D; Gale J; Grant W; Gray EK; Hoskin P; Khan MM; Manetta C; McPhail NJ; O'Sullivan JM; Parikh O; Perna C; Pezaro CJ; Protheroe AS; Robinson AJ; Rudman SM; Sheehan DJ; Srihari NN; Syndikus I; Tanguay JS; Thomas CW; Vengalil S; Wagstaff J; Wylie JP; Parmar MKB; Sydes MR;
Int J Cancer; 2022 Aug; 151(3):422-434. PubMed ID: 35411939
[TBL] [Abstract][Full Text] [Related]
20. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Rush HL; Murphy L; Morgans AK; Clarke NW; Cook AD; Attard G; Macnair A; Dearnaley DP; Parker CC; Russell JM; Gillessen S; Matheson D; Millman R; Brawley CD; Pugh C; Tanguay JS; Jones RJ; Wagstaff J; Rudman S; O'Sullivan JM; Gale J; Birtle A; Protheroe A; Gray E; Perna C; Tolan S; McPhail N; Malik ZI; Vengalil S; Fackrell D; Hoskin P; Sydes MR; Chowdhury S; Gilbert DC; Parmar MKB; James ND; Langley RE
J Clin Oncol; 2022 Mar; 40(8):825-836. PubMed ID: 34757812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
